J. L. Torres

Lack of p38 activation in T cells increases IL-35 production and protects against obesity by promoting thermogenesis

This study shows that inhibiting p38 in T cells increases IL-35 production, which enhances thermogenesis and protects against obesity.

Evolving spike-protein N-glycosylation in SARS-CoV-2 variants

This study compares N-glycan processing in SARS-CoV-2 spike-proteins across variants to understand immune evasion mechanisms.

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 that target conserved regions on the spike RBD, showing resistance to antigenic drift and suggesting potential vaccine targets.

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

This study shows bispecific antibodies combine the neutralizing breadth and potency of parental antibodies to neutralize SARS-CoV and SARS-CoV-2 variants, including Omicron.

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants

This paper identifies a broadly neutralizing antibody against SARS-CoV-2 that targets the receptor-binding site and remains effective against multiple Omicron subvariants.

Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual

This study identifies broadly neutralizing monoclonal and bispecific antibodies from a Gamma variant-infected individual that effectively neutralize multiple SARS-CoV-2 variants.

Affinity-matured homotypic interactions induce spectrum of PfCSP-antibody structures that influence protection from malaria infection

The paper analyzes structural and functional properties of antibodies targeting PfCSP, showing how homotypic interactions and affinity maturation influence protection against malaria.

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

The paper evaluates the potency of mAb J08 against SARS-CoV-2 variants using cell-based assays and cryo-EM, showing its resistance to escape mutations and broad binding capability.

A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant

This paper identifies two potent monoclonal antibodies from an Indian donor that neutralize SARS-CoV-2 variants including Delta, showing protection in a mouse model.

Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation

This study shows that germinal center B cells can persist and continue to mutate for 29 weeks after a single immunization, leading to long-lasting antibody responses.

A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

The paper identifies a novel S2 epitope recognized by a public antibody class in SARS-CoV-2-reactive B cells, which becomes exposed on vaccine-optimized spike proteins.

Structural mapping of antibody landscapes to human betacoronavirus spike proteins

The paper maps epitopes of polyclonal antibodies against beta-coronavirus spike proteins in human sera, revealing cross-reactive patterns between seasonal and SARS-2 infections.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques

This study shows that rhesus macaques can be immunized to produce broadly neutralizing antibodies against multiple SARS-related viruses, highlighting differences in B cell repertoires between humans and macaques.

One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

This study shows that displaying HIV-1 Env trimers on two-component protein nanoparticles enhances autologous Tier-2 neutralizing antibody titers in rabbits.

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

This study shows SARS-CoV-2 spike protein binds to heparan sulfate and ACE2 on cells codependently, forming a complex that facilitates infection, suggesting potential therapeutic targets.

Visualization of the HIV-1 Env Glycan Shield Across Scales

This study uses cryo-EM, computational modeling, and mass-spectrometry to analyze the HIV-1 Env glycan shield's structure and dynamics, revealing how heterogeneity and interactions affect epitope accessibility and trimer stability.

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

The paper examines cross-reactive serum and memory B cell responses to SARS-CoV-2 and endemic coronaviruses, finding weak serum cross-reactivity but stronger memory B cell cross-reactivity.

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

The paper uses cryo-EM and glycan analysis to study the structure of a full-length SARS-CoV-2 spike protein in a vaccine candidate, revealing its stable prefusion conformation and novel trimer interactions.

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

The paper identifies a SARS-CoV-2 antibody that cross-neutralizes SARS-CoV by binding a conserved epitope and relies on avidity for neutralization.

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

This study identifies an alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 RBD, showing that longer CDR H3 can bind with different angles and interactions.

A strain-specific inhibitor of receptor-bound HIV-1 targets a pocket near the fusion peptide and offers a template for drug design

The paper identifies a strain-specific HIV-1 inhibitor targeting a pocket near the fusion peptide, demonstrating small molecules can disrupt viral fusion and offering a template for drug design.

Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates

This study maps antibody responses to HIV-1 envelope trimers in non-human primates, identifying strain-specific and conserved epitopes recognized by vaccine-induced antibodies.

HIV-1 Envelope and MPER antibody structures in lipid assemblies

This study presents methods to incorporate full-length HIV-1 Env into lipid assemblies for structural analysis, revealing the quaternary epitope of an MPER antibody and Env tilting during neutralization.

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics

This study compares native HIV-1 Env trimers with soluble SOSIP trimers, finding structural and antigenic similarities but differences in antibody binding and glycan composition.

Cryo-EM structure of the circumsporozoite protein of Plasmodium falciparum with a vaccine-elicited antibody reveals maturation of inter-antibody contacts

The paper presents a cryo-EM structure of Plasmodium falciparum CSP with vaccine-elicited antibodies, revealing a spiral conformation stabilized by inter-antibody contacts.